Nippon Chemiphar Co., Ltd.

J-Pharma Co., Ltd.

Shizuoka Prefectural University Corporation

Dethree Res. Lab. Inc.

Masuharu Hirano

Tomio Yamakawa

Daisuke Saito

Hitoshi Endou

Kunio Kobayashi

Tsuyoshi Endo

Hiroto Tanaka

Naohiko Anzai

Takafumi Muto

Shuji Noguchi

Yasunori Iwao

Takashi Ohta

Toshihisa Ishikawa

Shigeru Itai

Hikaru Saito

There is provided an activator of peroxisome proliferator-activated receptor &#x3b1; which contains: a compound represented by the following Formula (I); a tautomer or stereoisomer of the compound; or a pharmaceutically acceptable salt or solvate thereof (where, in a case where R, R, R, and Rdo not constitute a ring, in the Formula, R, R, R, R, R, and Rmay be the same as or different from each other and represent a hydrogen atom, a halogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, an alkyl group having 1 to 8 carbon atoms substituted with 1 to 3 halogen atoms, an alkoxy group having 1 to 8 carbon atoms substituted with 1 to 3 halogen atoms, a hydroxy group, an amino group, a carboxyl group, a mercapto group, an alkylsulfanyl group having 1 to 8 carbon atoms, a nitro group, or a cyano group).

Activator of peroxisome proliferator-activated receptor

The present invention relates to a solid dispersion containing a compound represented by General Formula (I): 

Solid dispersion

Provided are a compound represented by the following Formula (III), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof used as a therapeutic agent for gout or hyperuricemia. (In the Formula (III), R, R, R, and Rrepresent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, or a cyano group, Rand Rform a benzene ring or a 5-membered heteroaryl ring containing 1 to 3 heteroatoms, as a ring constituent element, selected from nitrogen atoms, oxygen atoms, and sulfur atoms together with two carbon atoms to which Rand Rare bonded, Rand Rform a benzene ring together with two carbon atoms to which Rand Rare bonded or represent any of the groups represented by Rdescribed above, Wrepresents CRor N, and where, Rrepresents any of the groups represented by R, Xrepresents an oxygen atom or a sulfur atom, Yrepresents an alkylene chain having 1 to 8 carbon atoms, and where, the alkylene chain may be substituted with an alkyl group having 1 to 8 carbon atoms and the alkylene chain may be a linear or branched alkylene chain, the branched alkylene chain may have a 3- to 7-membered ring formed by side chains bonded to carbon atoms which are the same as or different from each other, together with the carbon atoms to which the side chains are bonded and may have a double bond in the middle thereof, and Zrepresents COH). 

URAT1 inhibitor

An agent comprising, as an active ingredient, a xanthine oxidase inhibitor such as 2-[3-cyano-4-(4-fluorophenoxy)phenyl]-4-hydroxythiazolo[5,4-d]pyrimidine potassium salt, 2-[3-cyano-4-(4-fluorophenoxy)phenyl]thiazolo[5,4-d]pyrimidine, 2-(3-cyano-4-phenoxyphenyl)-4-hydroxythiazolo[5,4-d]pyrimidine, 2-(3-cyano-4-phenoxyphenyl)-4-hydroxythiazolo[5,4-d]pyrimidine potassium salt, 2-(3-cyano-4-phenoxyphenyl)thiazolo[5,4-d]pyrimidine, TMX-67, and FYX-051, which can be used as an agent for overcoming anti-cancer agent resistance.

Agent for overcoming resistance to anti-cancer agent

Growing community of inventors

Misato, Japan

Masuharu Hirano